Recent advancements and future submissions of silica core-shell nanoparticles
Copyright © 2021 Elsevier B.V. All rights reserved..
The core-shell silica-based nanoparticles (CSNPs) possess outstanding properties for developing next-generation therapeutics. CSNPs provide greater surface area owing to their mesoporous structure, which offers a high opportunity for surface modification. This review highlights the potential of core-shell silica-based nanoparticle (CSNP) based injectable nanotherapeutics (INT); its role in drug delivery, biomedical imaging, light-triggered phototherapy, Plasmonic enhancers, gene delivery, magnetic hyperthermia, immunotherapy, and potential as next-generation theragnostic. Specifically, the conceptual crosstalk on modern synthetic strategies, biodistribution profiles with a mechanistic view on the therapeutics loading and release modeling are dealt in detail. The manuscript also converses the challenges associated with CSNPs, regulatory hurdles, and their current market position.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:609 |
|---|---|
| Enthalten in: |
International journal of pharmaceutics - 609(2021) vom: 20. Nov., Seite 121173 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kalyane, Dnyaneshwar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7631-86-9 |
|---|
| Anmerkungen: |
Date Completed 09.11.2021 Date Revised 09.11.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijpharm.2021.121173 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331689413 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331689413 | ||
| 003 | DE-627 | ||
| 005 | 20231225214019.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijpharm.2021.121173 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1105.xml |
| 035 | |a (DE-627)NLM331689413 | ||
| 035 | |a (NLM)34627997 | ||
| 035 | |a (PII)S0378-5173(21)00979-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kalyane, Dnyaneshwar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recent advancements and future submissions of silica core-shell nanoparticles |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.11.2021 | ||
| 500 | |a Date Revised 09.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier B.V. All rights reserved. | ||
| 520 | |a The core-shell silica-based nanoparticles (CSNPs) possess outstanding properties for developing next-generation therapeutics. CSNPs provide greater surface area owing to their mesoporous structure, which offers a high opportunity for surface modification. This review highlights the potential of core-shell silica-based nanoparticle (CSNP) based injectable nanotherapeutics (INT); its role in drug delivery, biomedical imaging, light-triggered phototherapy, Plasmonic enhancers, gene delivery, magnetic hyperthermia, immunotherapy, and potential as next-generation theragnostic. Specifically, the conceptual crosstalk on modern synthetic strategies, biodistribution profiles with a mechanistic view on the therapeutics loading and release modeling are dealt in detail. The manuscript also converses the challenges associated with CSNPs, regulatory hurdles, and their current market position | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Bioimaging | |
| 650 | 4 | |a Core-shell nanoparticles | |
| 650 | 4 | |a Injectable nanotherapeutics | |
| 650 | 4 | |a Phototherapy | |
| 650 | 4 | |a Silica core | |
| 650 | 7 | |a Silicon Dioxide |2 NLM | |
| 650 | 7 | |a 7631-86-9 |2 NLM | |
| 700 | 1 | |a Kumar, Narendra |e verfasserin |4 aut | |
| 700 | 1 | |a Anup, Neelima |e verfasserin |4 aut | |
| 700 | 1 | |a Rajpoot, Kuldeep |e verfasserin |4 aut | |
| 700 | 1 | |a Maheshwari, Rahul |e verfasserin |4 aut | |
| 700 | 1 | |a Sengupta, Pinaki |e verfasserin |4 aut | |
| 700 | 1 | |a Kalia, Kiran |e verfasserin |4 aut | |
| 700 | 1 | |a Tekade, Rakesh Kumar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of pharmaceutics |d 1992 |g 609(2021) vom: 20. Nov., Seite 121173 |w (DE-627)NLM07779785X |x 1873-3476 |7 nnns |
| 773 | 1 | 8 | |g volume:609 |g year:2021 |g day:20 |g month:11 |g pages:121173 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijpharm.2021.121173 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 609 |j 2021 |b 20 |c 11 |h 121173 | ||